Trial Profile
Safety and clinical efficacy of abetimus sodium (LJP-394) in prevention of renal flares in patients with systemic lupus erythematosus and a history of renal disease.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 10 Jul 2012
Price :
$35
*
At a glance
- Drugs Abetimus (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- 04 Aug 2011 New trial record